Innoviva (INVA) Expected to Announce Quarterly Earnings on Thursday

Innoviva (NASDAQ:INVA) is expected to issue its quarterly earnings data before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of $0.34 per share and revenue of $92.59 million for the quarter.

Innoviva (NASDAQ:INVA) last released its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $0.57 EPS for the quarter. Innoviva had a return on equity of 20.84% and a net margin of 18.31%. The business had revenue of $91.81 million for the quarter. On average, analysts expect Innoviva to post $0 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Innoviva Trading Down 1.2 %

Innoviva stock opened at $17.57 on Wednesday. The company has a current ratio of 1.79, a quick ratio of 1.64 and a debt-to-equity ratio of 0.38. Innoviva has a 12 month low of $14.32 and a 12 month high of $21.28. The stock’s 50 day simple moving average is $18.04 and its two-hundred day simple moving average is $18.85. The firm has a market cap of $1.10 billion, a PE ratio of 25.46 and a beta of 0.55.

Wall Street Analyst Weigh In

Separately, StockNews.com lowered Innoviva from a “buy” rating to a “hold” rating in a research report on Saturday, February 22nd.

About Innoviva

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.